10 completed, 1 withdrawn. 6 Phase 1, 3 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Not applicable | 3 | Completed 3 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Dermatitis, Phototoxic: new trials by email Literature Review of Dermatitis, Phototoxic trials Research Report on Dermatitis, Phototoxic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Photosensitization of a Scar Gel Scar gel - Sensitivity, Contact, Photosensitivity | Not applicable | Completed | Herbarium Laboratorio Botanico Ltda | 55 | 2025-01-13 | 2025-03-14 |
| Phototoxicity of Frequently Prescribed Medicines Single oral dose of selected medicines, respectively, UVA and UVB radiation - Phototoxicity | Not applicable | Completed | Medical University of Vienna | 12 | 2022-09-22 | 2024-11-29 |
| Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects KX01 ointment 1%, Placebo ointment - Healthy Volunteer | Phase 1 | Completed | PharmaEssentia | 20 | 2021-11-16 | 2022-02-18 |
| Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation - Phototoxicity | Phase 1 | Completed | MC2 Therapeutics | 35 | 2019-02-27 | 2020-02-12 |
| Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment Photoderm Max lait SPF50+, Photoderm Max Stick SPF50+ - Phototoxicity | Not applicable | Completed | Michele Sayag | 30 | 2016-07-01 | 2019-08-22 |
| Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects Butenafine HCl 1% (BAY1896425) - Dermatitis, Phototoxic | Phase 3 | Completed | Bayer | 32 | 2013-06-24 | 2020-11-13 |
| Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light Solar Protection Formula SPF® 60, Photobiological testing - High-grade Dysplasia in Barrett Esophagus, Non Small Cell Lung Cancer | Phase 2 | Withdrawn | Pinnacle Biologics Inc. | 2013-05-01 | 2014-03-04 | |
| TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light TMC435, Placebo, Ciprofloxacin - Hepatitis C Virus | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 49 | 2010-07-01 | 2013-05-06 |
| A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light - Acne Vulgaris | Phase 1 | Completed | Stiefel, a GSK Company | 38 | 2010-04-01 | 2017-06-20 |
| Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment Xenaderm, Placebo - Healthy | Phase 1 | Completed | Healthpoint | 38 | 2008-02-01 | 2014-01-13 |
| Clinical Evaluation of the Photoallergy Potential of Atralin Gel Atralin (tretinoin) gel, 0.05% - Healthy | Phase 1 | Completed | Coria Laboratories, Ltd. | 40 | 2008-01-01 | 2008-05-06 |
Photosensitivity Disorders (2) · Acne Vulgaris (1) · Carcinoma, Non-Small-Cell Lung (1) · Dermatitis, Contact (1) · Drug-Related Side Effects and Adverse Reactions (1) · Esophageal Neoplasms (1) · Hepatitis C (1)
Dermatitis (11) · Dermatitis, Irritant (11) · Skin Diseases (11) · Skin Diseases, Eczematous (11) · Skin and Connective Tissue Diseases (11) · Dermatitis, Contact (10) · Photosensitivity Disorders (9) · Digestive System Diseases (2) · Acneiform Eruptions (1) · Blood-Borne Infections (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Chemically-Induced Disorders (1) · Communicable Diseases (1) · Digestive System Neoplasms (1)
Radiation (2) · Ciprofloxacin (1) · Gels (1) · Granulex (1) · Light (1) · Simeprevir (1) · Tretinoin (1) · butenafine (1)
Bayer (1) · Coria Laboratories, Ltd. (1) · Healthpoint (1) · Herbarium Laboratorio Botanico Ltda (1) · MC2 Therapeutics (1) · Medical University of Vienna (1) · Michele Sayag (1) · PharmaEssentia (1) · Pinnacle Biologics Inc. (1) · Stiefel, a GSK Company (1) · Tibotec Pharmaceuticals, Ireland (1)
United States (4) · Austria (1) · Brazil (1) · France (1) · Japan (1)
Brigitte Dreno, MD (1) · Hisakuni Sekino (1) · Innes Cargill, PhD (1) · Jonathan S Dorsik (1) · Joseph W Stanfield, MS (1)